Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,918.28 ($25.66) and traded as high as GBX 1,924 ($25.74). Hikma Pharmaceuticals shares last traded at GBX 1,905 ($25.48), with a volume of 589,574 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms recently commented on HIK. Berenberg Bank upgraded shares of Hikma Pharmaceuticals to a “buy” rating and lifted their target price for the stock from GBX 2,100 ($28.09) to GBX 2,400 ($32.10) in a research note on Monday, September 2nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 2,750 ($36.78) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of GBX 2,325 ($31.10).

Hikma Pharmaceuticals Trading Down 0.4 %

The stock has a 50-day moving average of GBX 1,949.43 and a 200 day moving average of GBX 1,918.28. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The stock has a market cap of £4.23 billion, a PE ratio of 2,976.56, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, August 15th were issued a $0.32 dividend. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 9,687.50%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.